Clinical trials in Swidnica – page 10

985 clinical trials in Swidnica, Poland across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in PolandBadaniaKliniczne.pl

Swidnica at a glance

985

clinical trials

Research sites1

Quick filters

985 trials in Swidnica

Open in trial search

Hepatic cirrhosis+2

Recruiting

Study on Efruxifermin for Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) or Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Investigational

Study on Efruxifermin for Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) or Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Efruxifermin
Sponsor:Akero Therapeutics Inc.

Contact Research Centre

Chronic lymphocytic leukaemia+1

Recruiting

Efficacy and Safety of Three Different Doses of Pirtobrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Previously Received BTK Inhibitor Treatment

InvestigationalNo placebo

Efficacy and Safety of Three Different Doses of Pirtobrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Previously Received BTK Inhibitor Treatment

InvestigationalNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Pirtobrutinib
Sponsor:Eli Lilly & Co.

Contact Research Centre

Dementia Alzheimer's type

Recruiting

Efficacy and Safety of RO7568282 in Adults with Early Symptomatic Alzheimer’s Disease

Investigational

Efficacy and Safety of RO7568282 in Adults with Early Symptomatic Alzheimer’s Disease

Investigational

Poland

Participants:18–64 years · 65+ years
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Small cell lung cancer

Recruiting

Study of BI 764532 with drug combination in patients with extensive‑stage small cell lung cancer

Registered drugNo placebo

Study of BI 764532 with drug combination in patients with extensive‑stage small cell lung cancer

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Type 2 diabetes mellitus

Recruiting

Zenagamtide versus semaglutide: a study of blood sugar and weight reduction in adults with type 2 diabetes inadequately controlled on metformin and/or SGLT2 inhibitor

Investigational

Zenagamtide versus semaglutide: a study of blood sugar and weight reduction in adults with type 2 diabetes inadequately controlled on metformin and/or SGLT2 inhibitor

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Semaglutide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Short stature

Recruiting

Weekly Somatrogon versus Daily Somatropin in Children with Small for Gestational Age or Idiopathic Short Stature

Registered drugNo placebo

Weekly Somatrogon versus Daily Somatropin in Children with Small for Gestational Age or Idiopathic Short Stature

Registered drugNo placebo

Poland

Participants:0–17 years
Substances:Somatrogon
Sponsor:Schneider Children's Medical Center Of Israel

Contact Research Centre

Ductal adenocarcinoma of pancreas

Recruiting

A Study of Setidegrasib with Chemotherapy Drug Combination as First‑Line Treatment in Adults with KRAS G12D‑mutated Metastatic Pancreatic Cancer

Investigational

A Study of Setidegrasib with Chemotherapy Drug Combination as First‑Line Treatment in Adults with KRAS G12D‑mutated Metastatic Pancreatic Cancer

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:ASP3082
Sponsor:Astellas Pharma Global Development Inc.

Contact Research Centre

Iron deficiency

Recruiting

Effect of Ferric Carboxymaltose, Ferrous Sulfate, and Sodium Chloride vs Placebo on Physical Performance in Frail Elderly with Iron Deficiency and Cardiovascular Disease

Registered drug

Effect of Ferric Carboxymaltose, Ferrous Sulfate, and Sodium Chloride vs Placebo on Physical Performance in Frail Elderly with Iron Deficiency and Cardiovascular Disease

Registered drug

Poland

Participants:65+ years
Substances:Sodium Chloride
Sponsor:Wroclaw Medical University

Contact Research Centre

Chronic myeloid leukaemia

Recruiting

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo

Poland

Participants:0–17 years · 18–64 years · 65+ years
Substances:Bosutinib
Sponsor:Novartis Pharma AG

Contact Research Centre

Anaemia+1

Recruiting

A Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Registered drugNo placebo

A Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Epoetin Alfa
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Clear cell renal cell carcinoma

Recruiting

A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

Registered drug

A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:AB521
Sponsor:Arcus Biosciences Inc.

Contact Research Centre

Axial spondyloarthritis+1

Recruiting

Study on the Effects of Upadacitinib for Patients with Active Psoriatic Arthritis and Axial Spondyloarthritis

Investigational

Study on the Effects of Upadacitinib for Patients with Active Psoriatic Arthritis and Axial Spondyloarthritis

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Upadacitinib
Sponsor:Care Arthritis Ltd.

Contact Research Centre

Other cities in Poland

The busiest research cities in the country

All 236 cities in Poland

Clinical research in Swidnica

What the registry says about research in the country

01 Inflammatory Conditions

Innovative research focusing on inflammatory disorders, including trials evaluating new treatments for psoriatic arthritis and rheumatoid arthritis. Studies aim to assess novel therapeutic approaches using biologics and targeted medications.

Psoriatic Arthritis Studies
Rheumatoid Arthritis Treatment
Inflammatory Disease Management

Advanced therapies being tested to improve patient outcomes and quality of life.

02 Gastrointestinal Research

Comprehensive studies investigating treatments for inflammatory bowel diseases, including trials for Crohn's Disease and ulcerative colitis. Research focuses on novel therapeutic agents and long-term disease management.

Crohn's Disease Therapies
Ulcerative Colitis Treatments
Long-term Disease Management

Multiple trials exploring innovative approaches to treating gastrointestinal conditions.

03 Metabolic and Pain Management

Studies addressing obesity, knee osteoarthritis, and chronic pain conditions. Research includes evaluation of new medications for weight management and innovative approaches to pain relief.

Weight Management Therapies
Osteoarthritis Treatment
Pain Management Solutions

Cutting-edge research combining multiple therapeutic approaches for complex conditions.

04 Specialty Conditions

Focused research on unique conditions including thyroid eye disease, chronic spontaneous urticaria, and rotator cuff tendinopathy. Studies aim to develop targeted treatments for these specific medical needs.

Endocrine Disorders
Autoimmune Conditions
Musculoskeletal Treatments

Specialized therapeutic approaches for distinct medical conditions.

Back to Poland All countries